+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor

RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor

Structure 20(11): 1971-1982

Osteoprotegerin (OPG) and receptor activator of nuclear factor κB (RANK) are members of the tumor necrosis factor receptor (TNFR) superfamily that regulate osteoclast formation and function by competing for RANK ligand (RANKL). RANKL promotes osteoclast development through RANK activation, while OPG inhibits this process by sequestering RANKL. For comparison, we solved crystal structures of RANKL with RANK and RANKL with OPG. Complementary biochemical and functional studies reveal that the monomeric cytokine-binding region of OPG binds RANKL with ∼500-fold higher affinity than RANK and inhibits RANKL-stimulated osteoclastogenesis ∼150 times more effectively, in part because the binding cleft of RANKL makes unique contacts with OPG. Several side chains as well as the C-D and D-E loops of RANKL occupy different orientations when bound to OPG versus RANK. High affinity OPG binding requires a 90s loop Phe residue that is mutated in juvenile Paget's disease. These results suggest cytokine plasticity may help to fine-tune specific tumor necrosis factor (TNF)-family cytokine/receptor pair selectivity.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333158

Download citation: RISBibTeXText

PMID: 23039992

DOI: 10.1016/j.str.2012.08.030

Related references

Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clinical and Experimental Immunology 138(3): 491-498, 2004

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget 5(16): 6647-6653, 2015

Mechanism of binding of the decoy receptor Osteoprotegerin to the bone resorption factor RANK-L. Biophysical Journal 86(1): 510a, January, 2004

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33(1): 199-206, 2013

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochemical and Biophysical Research Communications 347(2): 460-467, 2006

Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. Journal of Immunology 189(1): 245-252, 2012

The functions of the avian receptor activator of NF-κB ligand (RANKL) and its receptors, RANK and osteoprotegerin, are evolutionarily conserved. Developmental and Comparative Immunology 51(1): 170-184, 2016

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Molecular Medicine Reports 11(5): 3212-3218, 2016

Osteoprotegerin, RANK, RANKL. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 145(2): 61-64, 2002

Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & Therapy 9 Suppl 1: S1-S1, 2007

Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Annales D'endocrinologie 67(2): 139-141, 2006

RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 38(2): 161-170, 2005

Comparison of the rank, RANKL and osteoprotegerin expression in the osteoarthritis. 2007